Real-World Case Study: Pharmacy Renomination Performance

This case study is based on real patient engagement work carried out by Jennifer during her time as a pharmacy management consultant working with a community pharmacy.

Join Partner Programme

The data reflects actual patient contact outcomes over a nine-month period

The data below provides a realistic benchmark for what can be achieved when lost patients are contacted promptly and professionally.

Why Timing Matters

Time from patient departure is critical.

The longer it takes to make contact with a patient who has moved their nomination, the lower the likelihood of successful renomination. The results below are based on contacting patients within 45 days of their nomination being lost and this is the maximum time we would contact legitimate lost nominations

Early engagement significantly improves:

Patient recall
Willingness to discuss nomination
Overall conversion rates

Contact Methodology Used

During the period covered by this case study, patient contact was intentionally limited.

In many instances, patients who were unavailable on the first call were not followed up, meaning no second or third attempt was made to re-establish contact. This approach was driven by time constraints rather than best-practice engagement strategy.

As a result, the outcomes shown reflect successful first-contact conversations only, without the benefit of structured follow-up.

By contrast, the Renominate service is designed to maximise ethical contact opportunities by:

Making multiple attempts over different days and times
Including early evening and weekend contact windows
Allowing patients adequate opportunity to respond at their convenience

Because the results in this case study were achieved largely without follow-up activity, they should be viewed as conservative and representative of baseline performance rather than full optimisation.

Nine-Month Results Overview

Lost patient records provided:

4,150 patients

Successful renominations:

1,079 patients

Overall conversion rate:

26%

This conversion rate was achieved without extensive second or third follow-up attempts, reinforcing the importance of timing and structured engagement.

Financial Impact Breakdown

The following figures are based on national prescription income averages and are provided for illustration only.

Average annual prescription income per patient:

£48

Without Renomination

Total lost patients:

4,150

Estimated annual income loss:

£199,200

With Renomination

Patients successfully renominated:

1,079

Recovered annual income:

£51,792

Cost Comparison Using Renominate Pricing

If this same activity had been delivered using Renominate’s current pricing structure:

Estimated Renominate service cost:

£10,790

Net Position

Net profit after 12 months:

£41,002

Net profit after 6 months:

£15,106

Net profit after 3 months:

£2,158

This demonstrates that the renomination service alone typically pays for itself in under three months, with all subsequent prescription income representing pure retained revenue.

Why the 6-Month Guarantee Matters

Renominate includes a six-month renomination guarantee to protect pharmacy ROI.

This ensures:

Each successfully renominated patient remains active for a minimum period, or
The nomination is replaced at no additional cost

As a result, pharmacies typically achieve:

Approximately 50% net profit by month six
100% retained value thereafter, for the duration of the patient's nomination

Founder Partner Opportunity

We are currently welcoming a limited number of pharmacies to join as Founder Partners during the structured launch phase of the Renominate programme.

Founder Partners participate at the ground-floor stage of a carefully designed retention and digital credibility framework. During this phase, each partner receives direct oversight and measured implementation support to ensure long-term stability and success.

Founder Partner status includes:

• Direct founder-led implementation and strategic oversight
• Priority onboarding within the structured rollout phase
• Protected long-term commercial positioning within the programme
• Preferential access to all Renominate services and future enhancements
• Participation within a limited, quality-controlled launch cohort

Launch intake is intentionally restricted to ensure every Founder Partner receives the level of attention and structure the programme requires.